Thus, the goal of the present study was to gain insight into the serum levels of sTLR4 and sCD14 in SCPs and NSCPs to assess their correlation with hematological abnormalities and to investigate their potential clinical utility as a clinical severity marker forCOVID-19 patients.To the best of our knowledge, this is the first study that evaluated the serum levels of sTLR4 as an endogenous negative regulator of TLR4 signaling in patients with COVID-19. Here, TLR4 is linked to COVID-19.